| Quarterly Financials | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 |
Revenue  | 178 | 198 | 193 | 203 | 205 | 225 | 225 | 210 | 146 | 291 | 279 | 294 | 346 | 308 | 296 | 312 | 283 | 305 | 292 | 284 | 280 | 310 | 293 | 334 | 316 | 353 | 325 |
| Expenses | 132 | 146 | 142 | 145 | 156 | 161 | 159 | 173 | 131 | 198 | 188 | 195 | 224 | 212 | 218 | 231 | 211 | 221 | 215 | 212 | 214 | 234 | 226 | 251 | 235 | 260 | 251 |
| EBITDA | 46 | 53 | 51 | 58 | 49 | 64 | 66 | 37 | 15 | 94 | 90 | 99 | 122 | 96 | 78 | 81 | 72 | 83 | 77 | 72 | 66 | 76 | 67 | 83 | 81 | 93 | 75 |
| Operating Profit % | 25 % | 25 % | 26 % | 28 % | 24 % | 28 % | 29 % | 16 % | 8 % | 32 % | 32 % | 33 % | 31 % | 30 % | 26 % | 24 % | 24 % | 26 % | 25 % | 25 % | 23 % | 24 % | 22 % | 24 % | 25 % | 26 % | 22 % |
| Depreciation | 5 | 5 | 5 | 5 | 8 | 9 | 11 | 11 | 10 | 11 | 11 | 14 | 13 | 15 | 17 | 18 | 21 | 22 | 23 | 23 | 21 | 22 | 25 | 26 | 26 | 27 | 28 |
| Interest | 0 | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 6 | 3 | 5 | 6 | 8 | 7 | 6 | 6 | 6 | 6 | 5 | 6 | 5 | 5 | 5 |
| Profit Before Tax | 42 | 48 | 46 | 52 | 39 | 53 | 53 | 23 | 4 | 81 | 78 | 82 | 103 | 78 | 56 | 57 | 43 | 55 | 48 | 42 | 39 | 48 | 37 | 51 | 51 | 61 | 42 |
| Tax | 14 | 18 | 14 | 17 | 12 | 10 | 11 | 8 | 1 | 21 | 19 | 20 | 28 | 19 | 15 | 16 | 9 | 14 | 12 | 8 | 10 | 13 | 10 | 14 | 13 | 15 | 11 |
| Net Profit | 27 | 30 | 31 | 35 | 27 | 43 | 42 | 16 | 3 | 61 | 59 | 61 | 75 | 58 | 41 | 40 | 34 | 41 | 36 | 34 | 29 | 36 | 27 | 37 | 38 | 47 | 32 |
| EPS in ₹ | 4.83 | 6.14 | 6.26 | 6.87 | 5.34 | 8.57 | 8.38 | 3.09 | 0.57 | 11.88 | 11.50 | 12.05 | 14.65 | 11.39 | 8.02 | 7.81 | 6.53 | 7.88 | 6.99 | 6.51 | 5.62 | 6.92 | 5.30 | 7.11 | 7.41 | 9.08 | 6.12 |
Metropolis Healthcare
1,695.60
+11.60
(0.69%)
Market Cap
8,695.23 Cr
EPS
24.95
PE Ratio
56.61
Dividend Yield
0.24 %
Industry
Healthcare Services52 Week High
2,318.30
52 Week Low
1,315.00
PB Ratio
7.28
Debt to Equity
0.22
Investment Returns
In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from16 analysts
Company News
View All News
Metropolis Healthcare to Consider Q4 Results on May 132 days ago
Metropolis Healthcare has announced that it will consider its fourth quarter (Q4) financial results on May 13. This indicates that the company is preparing to release its earnings report for the most recent fiscal quarter.
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
2,852.30 | #1 23,842.87 | 48.19 | #1 2,295.80 | 11.52 | #1 362 | 81.24 | 62.56 | |
1,006.40 | 10,329.32 | 72.41 | 568.60 | 20.11 | 120 | 35.77 | 47.92 | |
1,695.60 | #3 8,695.23 | #7 56.61 | #3 1,216.80 | #9 4.59 | #2 129 | #8 15.38 | 54.22 | |
922.60 | 4,889.18 | 53.33 | 581.30 | 8.63 | 70 | 25.58 | 73.07 | |
717.25 | 2,315.98 | 30.09 | 636.40 | 25.65 | 57 | 49.23 | 40.85 | |
1,749.00 | 1,501.07 | 30.16 | 86.70 | 25.47 | 32 | 58.82 | 51.17 | |
248.15 | 789.38 | #1 7.66 | 1,436.10 | 35.04 | 6 | -1,081.25 | 45.22 | |
277.90 | 197.29 | 17.55 | 63.00 | #1 248.07 | 7 | 133.33 | 28.48 | |
116.35 | 81.03 | 65.08 | 36.90 | 6.34 | 1 | 0.00 | 46.09 | |
63.50 | 65.36 | 77.96 | 13.60 | -8.11 | -3 | #1 142.86 | 37.94 |
Automatic Screeners on ScanX
Growth Rate
Revenue Growth
4.59 %
Net Income Growth
-10.39 %
Cash Flow Change
6.87 %
ROE
-19.21 %
ROCE
-13.10 %
EBITDA Margin (Avg.)
-8.13 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Total Assets | 530 | 553 | 752 | 1,004 | 1,530 | 1,502 | 1,555 |
| Fixed Assets | 207 | 213 | 296 | 343 | 1,059 | 1,121 | 1,177 |
| Current Assets | 300 | 305 | 397 | 609 | 393 | 303 | 316 |
| Capital Work in Progress | 0 | 6 | 3 | 0 | 6 | 20 | 0 |
| Investments | 102 | 33 | 14 | 10 | 16 | 15 | 55 |
| Other Assets | 221 | 301 | 439 | 651 | 450 | 347 | 323 |
| Total Liabilities | 530 | 553 | 752 | 1,004 | 1,530 | 1,502 | 1,555 |
| Current Liabilities | 91 | 125 | 170 | 204 | 302 | 265 | 246 |
| Non Current Liabilities | 11 | 8 | 58 | 92 | 341 | 246 | 210 |
| Total Equity | 429 | 420 | 525 | 708 | 888 | 991 | 1,099 |
| Reserve & Surplus | 405 | 409 | 513 | 696 | 876 | 978 | 1,086 |
| Share Capital | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Net Cash Flow | 4 | 14 | -1 | 18 | 8 | 56 | 279 | -321 | 3 | -6 |
| Investing Activities | -56 | 96 | -86 | 1 | 36 | -104 | 63 | -736 | 48 | -89 |
| Operating Activities | 70 | 91 | 102 | 104 | 90 | 215 | 249 | 253 | 247 | 264 |
| Financing Activities | -10 | -174 | -17 | -87 | -118 | -55 | -33 | 163 | -292 | -181 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 |
| Promoter | 50.38 % | 50.37 % | 50.33 % | 49.50 % | 49.79 % | 49.79 % | 49.76 % | 49.76 % | 49.75 % | 49.75 % | 49.74 % | 49.74 % | 49.67 % | 49.62 % | 49.43 % | 49.40 % | 48.90 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 24.29 % | 0.00 % | 18.90 % | 18.25 % | 18.56 % | 16.73 % | 15.29 % |
| DIIs | 15.34 % | 14.22 % | 11.77 % | 10.63 % | 15.32 % | 13.85 % | 11.88 % | 13.30 % | 13.64 % | 14.47 % | 16.86 % | 20.28 % | 24.86 % | 27.43 % | 28.02 % | 30.00 % | 30.30 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 3.95 % | 3.98 % | 4.24 % | 6.50 % | 9.14 % | 9.26 % | 9.45 % | 9.73 % | 8.53 % | 8.15 % | 7.78 % | 6.63 % | 5.24 % | 4.07 % | 3.54 % | 3.34 % | 3.84 % |
| Others | 30.33 % | 31.43 % | 33.66 % | 33.37 % | 25.75 % | 27.10 % | 28.91 % | 27.21 % | 28.08 % | 27.62 % | 1.32 % | 23.35 % | 1.33 % | 0.63 % | 0.45 % | 0.53 % | 1.68 % |
| No of Share Holders | 30,679 | 33,527 | 43,552 | 64,168 | 79,895 | 86,404 | 90,090 | 91,452 | 84,269 | 89,692 | 86,249 | 79,878 | 68,283 | 58,108 | 51,852 | 48,572 | 49,293 |
Dividend History
Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 0.00 | 0.00 | 13.26 | 8 | 8 | 8 | 8 | 4 | 0.00 |
| Dividend Yield (%) | 0.00 | 0.00 | 0.00 | 1.03 | 0.36 | 0.39 | 0.67 | 0.46 | 0.26 | 0.00 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 04 Feb 2025 |  Quarterly Result Announcement | NA | 04 Feb 2025 | 1,708.90 | 1,757.75 |
| 08 Nov 2024 | Quarterly Result Announcement | NA | 08 Nov 2024 | 2,119.10 | 2,112.60 |
| 21 Aug 2024 |  Annual General Meeting | NA | 21 Aug 2024 | 2,098.30 | 2,091.55 |
| 17 Nov 2023 |  Dividend | ₹ 4.00 /share | 17 Nov 2023 | 1,472.25 | 1,606.85 |
| 23 Feb 2023 | Dividend | ₹ 8.00 /share | 23 Feb 2023 | 1,289.35 | 1,348.60 |
| 22 Feb 2022 | Dividend | ₹ 8.00 /share | 21 Feb 2022 | 2,459.95 | 1,976.10 |
| 19 Feb 2021 | Dividend | ₹ 8.00 /share | 17 Feb 2021 | 2,163.55 | 2,011.85 |
Announcements
Board Meeting Intimation for Intimation Of Board Meeting Under Regulation 29 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015
2 days ago
2 days agoAnnouncement under Regulation 30 (LODR)-Allotment of ESOP / ESPSApr 18, 2025
Apr 18, 2025Announcement under Regulation 30 (LODR)-Updates on AcquisitionApr 16, 2025
Apr 16, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 10, 2025
Apr 10, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 07, 2025
Apr 07, 2025Announcement under Regulation 30 (LODR)-AcquisitionApr 07, 2025
Apr 07, 2025Business Update For Q4FY25Apr 05, 2025
Apr 05, 2025Closure of Trading WindowMar 31, 2025
Mar 31, 2025Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 (Listing Regulations)Mar 29, 2025
Mar 29, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Mar 29, 2025
Mar 29, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Mar 29, 2025
Mar 29, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Mar 28, 2025
Mar 28, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Mar 28, 2025
Mar 28, 2025Announcement under Regulation 30 (LODR)-Updates on AcquisitionMar 22, 2025
Mar 22, 2025Announcement under Regulation 30 (LODR)-Change in DirectorateMar 17, 2025
Mar 17, 2025Announcement under Regulation 30 (LODR)-Change in ManagementMar 17, 2025
Mar 17, 2025Board Meeting Outcome for Outcome Of Board Meeting Held On Monday March 17 2025Mar 17, 2025
Mar 17, 2025Grant Of Restrictive Stock Units Under The Metropolis - Restrictive Stock Unit Plan 2020Mar 17, 2025
Mar 17, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 04, 2025
Mar 04, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 03, 2025
Mar 03, 2025Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Mar 03, 2025
Mar 03, 2025Announcement under Regulation 30 (LODR)-AcquisitionMar 03, 2025
Mar 03, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 24, 2025
Feb 24, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Feb 18, 2025
Feb 18, 2025Announcement under Regulation 30 (LODR)-Change in ManagementFeb 13, 2025
Feb 13, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptFeb 11, 2025
Feb 11, 2025 Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportFeb 10, 2025
Feb 10, 2025Shareholder Meeting / Postal Ballot-Outcome of Postal_BallotFeb 10, 2025
Feb 10, 2025Announcement under Regulation 30 (LODR)-Updates on AcquisitionFeb 06, 2025
Feb 06, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 05, 2025
Feb 05, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeFeb 05, 2025
Feb 05, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 05, 2025
Feb 05, 2025Announcement under Regulation 30 (LODR)-Investor PresentationFeb 04, 2025
Feb 04, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 04, 2025
Feb 04, 2025Integrated Filing (Financial)Feb 04, 2025
Feb 04, 2025Board Meeting Outcome for The Meeting Held Today (February 04 2025)Feb 04, 2025
Feb 04, 2025Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter And Nine Months Ended December 31 2024Feb 04, 2025
Feb 04, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 04, 2025
Feb 04, 2025Announcement under Regulation 30 (LODR)-Change in ManagementJan 29, 2025
Jan 29, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJan 29, 2025
Jan 29, 2025Board Meeting Intimation for Considering And Approving The Unaudited Standalone And Consolidated Financial Results For The Quarter And Nine Months Ended December 31 2024Jan 29, 2025
Jan 29, 2025Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSJan 12, 2025
Jan 12, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJan 11, 2025
Jan 11, 2025Shareholder Meeting / Postal Ballot-Notice of Postal BallotJan 10, 2025
Jan 10, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 06, 2025
Jan 06, 2025Change In The Name Of The Registrar And Transfer Agent Of The CompanyJan 06, 2025
Jan 06, 2025Business Update For Q3FY25Jan 06, 2025
Jan 06, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Jan 03, 2025
Jan 03, 2025Closure of Trading WindowDec 31, 2024
Dec 31, 2024Transcript Of Investor Conference CallDec 16, 2024
Dec 16, 2024Technical Indicators
RSI(14)
Neutral 54.22
ATR(14)
Volatile 54.50
STOCH(9,6)
Neutral 31.19
STOCH RSI(14)
Oversold 14.53
MACD(12,26)
Bearish -0.62
ADX(14)
Weak Trend 17.39
UO(9)
Bearish 53.32
ROC(12)
Uptrend And Accelerating 1.98
WillR(14)
Neutral -56.72
About Metropolis Healthcare
Metropolis Healthcare Limited is an Indian diagnostic services company operating across India and Africa. Founded in 1980 as a pathology partnership, it has evolved into a public company offering a wide range of clinical laboratory tests and profiles. The company operates through a hub and spoke model with 115 clinical laboratories, including a global reference laboratory in Mumbai, regional reference laboratories, satellite laboratories, and express laboratories. Metropolis provides services to both B2B and B2C markets, covering 197 cities in India and has operations in several African countries. The company offers approximately 3,487 clinical laboratory tests and 530 profiles, and has expanded its network through acquisitions and mergers. Metropolis is known for its quality diagnostics and has received awards for customer service and healthcare excellence.
Listing Date
15 Apr, 2019(6 Years,
-7 days)
Chairperson Name
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
